Biotech Values

[DewDiligence]

ENTA—What milestone payments (if any) are attached to ABT-493 and ABT-530?

For ABT-493, ENTA has two options: a) to earn (undisclosed) regulatory milestone payments and royalties on sales from ABBV; or b) to share with ABBV the profits and the development/commercialization costs of the ABT-493 + ABT-530 combination.

ENTA must decide which route to take before the start of phase-2b trials. Since the economic terms have not been disclosed, it’s hard to predict which way they will go.

Note: ABT-530 is wholly owned by ABBV, so under option a) above, royalties would be based on the portion of ABT-493 + ABT-530 sales attributable to ABT-493 (just as is being done for ABT-450 in ABBV/ENTA’s 3-DAA regimen).